Success Metrics

Clinical Success Rate
100.0%

Based on 4 completed trials

Completion Rate
100%(4/4)
Active Trials
1(20%)
Results Posted
25%(1 trials)

Phase Distribution

Ph phase_1
4
80%

Phase Distribution

4

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution4 total trials
Phase 1Safety & dosage
4(100.0%)

Highest Phase Reached

Phase 1

Trial Status & Enrollment

Completion Rate

100.0%

4 of 4 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

5

all time

Status Distribution
Active(1)
Completed(4)

Detailed Status

Completed4
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
5
Active
1
Success Rate
100.0%
Most Advanced
Phase 1

Trials by Phase

Phase 14 (100.0%)

Trials by Status

completed480%
active_not_recruiting120%

Recent Activity

1 active trials
Showing 5 of 5
completedphase_1

A Phase I Study With a Personalized NeoAntigen Cancer Vaccine in Melanoma

NCT01970358
active_not_recruitingphase_1

Safety and Immunogenicity of Personalized Genomic Vaccine and Tumor Treating Fields (TTFields) to Treat Glioblastoma

NCT03223103
completed

Identification of Immunogenic Neo-epitopes for the Development of Personalised Pancreatic Cancer Vaccines

NCT04379960
completedphase_1

Safety and Immunogenicity of Personalized Genomic Vaccine to Treat Malignancies

NCT02721043
completedphase_1

Phase I Oncovir Poly IC:LC and NY-ESO-1/gp100

NCT01008527

Clinical Trials (5)

Showing 5 of 5 trials
NCT01970358Phase 1

A Phase I Study With a Personalized NeoAntigen Cancer Vaccine in Melanoma

Completed
NCT03223103Phase 1

Safety and Immunogenicity of Personalized Genomic Vaccine and Tumor Treating Fields (TTFields) to Treat Glioblastoma

Active Not Recruiting
NCT04379960

Identification of Immunogenic Neo-epitopes for the Development of Personalised Pancreatic Cancer Vaccines

Completed
NCT02721043Phase 1

Safety and Immunogenicity of Personalized Genomic Vaccine to Treat Malignancies

Completed
NCT01008527Phase 1

Phase I Oncovir Poly IC:LC and NY-ESO-1/gp100

Completed

All 5 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
5